Biotech Co. Zymergen Hits Ch. 11 In Del. Eyeing Asset Sale

By Alex Wittenberg · October 3, 2023, 11:34 AM EDT

Biotechnology company Zymergen Inc. on Tuesday filed for Chapter 11 protection in Delaware with both assets and debts of $100 million to $500 million, saying it's seeking an asset sale and...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

Case Number

Court

Delaware

Nature of Suit

Date Filed

October 03, 2023

Recent Articles By Alex

June 07, 2024
Acorda Therapeutics Gets OK On $185M Ch. 11 Sale To Merz
March 01, 2024
Plaintiffs Blast Prison Health Co.'s 'Potemkin Village' Case
December 20, 2023
Stimwave Buyer Can Enforce Sale In 'Disturbing' Domain Row
December 19, 2023
Zymergen Gets Conditional OK For Ch. 11 Asset Sales
December 01, 2023
Leases Don't Disqualify Small Biz Bankruptcies, Court Rules
November 29, 2023
Oncology Co. Akumin Gets OK For Take-Private Ch. 11 Plan
November 06, 2023
Justices Grant Purdue Creditors Separate Argument Time
October 24, 2023
Med-Tech Co. UpHealth And 6 Units Get OK For Joint Ch. 11
October 23, 2023
High Court Told Purdue's Ch. 11 Liability Waiver Is Legal
October 19, 2023
Bankrupt Rite Aid's New Directors To Earn $50K Per Month